Change in number of shares and votes in Moberg Pharma

STOCKHOLM, July 31, 2015. The number of shares and votes in Moberg Pharma AB
(publ) has increased by 39,000 to 14,001,537 during July 2015. Therefore, there
are in total 14,001,537 shares and votes in the company as of July 31, 2015.
The reason for the increase is that warrants in Moberg Pharma have been
exercised under the company’s share-based incentive program.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.30 a.m. (CET) on July 31, 2015.
For additional information contact:
Peter Wolpert, CEO, Telephone: +46 (0)70 - 735 7135, E-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Telephone: +46 (0)70 - 766 60 30, E-mail:
anna.ljung@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Jointflex®,
Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail® (Emtrix® or
Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the
U.S., Canada and several EU markets and is currently being launched in Southeast
Asia. The company is growing organically as well as through acquisitions.
Internal development programs focuses on innovative drug delivery of proven
compounds and include two phase II assets, MOB-015 (onychomycosis) and BUPI
(oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the
company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic
Exchange Stockholm (OMX: MOB). For further information, please visit:
www.mobergpharma.com.